At FDA Urging, Drug Maker Pulls Opana ER Off Market
At the request of the U.S. Food and Drug Administration (FDA), Endo Pharmaceuticals has removed from the market its long-acting opioid pain medication, Opana ER (oxymorphone hydrochloride extended release), which some patients with arthritis take to manage chronic pain.
Continue reading At FDA Urging, Drug Maker Pulls Opana ER Off Market